As part of our continued efforts to share more information about the clinical evidence covered in the SCC’s Clinical Training Curriculum, our webinar series “Meet the Authors”, will give participants a unique opportunity to experience discussion with experts in the field of medical cannabis.
Don’t miss the July edition of “Canna Talk with Frye and Wilson-King” on July 22nd as we explore Clinical Endocannabinoid Deficiency with Ethan Russo, MD
These educational webinars are free for all to attend. The curriculum co-directors Patricia Frye, MD and Genester Wilson-King, MD will host informal conversations with Russo and discuss his line of research on the topic of Clinical Endocannabinoid Deficiency and clinical pearls he learned along the way. We will have the opportunity to delve deeper into the topics Dr. Russo presented in the SCC Clinical Training Module Clinical Endocannabinoid Deficiency. Learn more about Dr. Russo in the bio below.
Established cannabis clinicians as well as individuals new to the medical cannabis sphere are all invited to attend this conversation. This is a great platform for users who are enrolled in the Training Curriculum to ask follow-up questions that may have come up while they were taking the courses. Questions can be submitted beforehand or asked live during the webinar. Join us by registering via the link below.
Ethan Russo, MD is a board-certified neurologist, psychopharmacology researcher, and author. He is the Founder and CEO of Credo Science.
Previously, he was Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic. Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system, and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy.
He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru.
He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard University, and Johns Hopkins University.
He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over fifty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions.
He has consulted or lectured on these topics in 44 US states and Canadian provinces and 44 countries on six continents.